| Entries |
| Document | Title | Date |
|---|
| 20080207753 | Analogues of lipid mediators derived from omega-3 PUFAs and methods of use - The present invention is directed to compounds that are analogues of lipid mediators derived from a fish oil-derived fatty acid, eicosapentaenoic acid [C20:5 ω-3; EPA], but with a longer tissue half-life and enhanced bioactivity. These analogues may be used to treat inflammatory, angioproliferative, cardiovascular, thrombophlebotic, vascular, ocular, dermatologic, neurodegenerative, pulmonary, endocrine, reproductive, rheumatologic and gastrointestinal diseases. | 08-28-2008 |
| 20080255233 | Isomeric mixtures of dinitro-octylphenyl esters and synergistic fungicidal mixtures therefrom - The present invention relates to an isomeric composition comprising isomers of dinitro-octylphenyl esters, wherein the 2,6-dinitro-4-(1-propylpentyl)phenyl ester isomer is present in an amount of less than 0.1 weight percent, based on the total weight of the isomeric composition and to synergistic fungicidal mixtures therefrom. | 10-16-2008 |
| 20080319069 | Spider esters in personal care applictions - The present invention is drawn to a process for providing emolliency to the skin using a series so called “spider esters”. These esters are derived from poly-hydroxy functional compounds sequentially reacted with ethylene oxide or propylene oxide, followed by the reaction of the alkoxylate with fatty acid. The resulting products are called spider esters because they resemble the spider, wherein appendages are alkoxylated esters. The restrictions this orientation imposes on rotation allows for the preparation of polar esters that have little or no water solubility, and provide both moisturization to the skin and emolliency by reducing transepidermal water loss. | 12-25-2008 |
| 20090005447 | METHODS, COMPOUNDS, AND COMPOSITIONS FOR REDUCING BODY FAT AND MODULATING FATTY ACID METABOLISM - Methods, pharmaceutical compositions, and compounds for reducing body weight, modulating body lipid metabolism, and reducing food intake in mammals are provided. The compounds of the invention include fatty acid ethanolamide compounds, homologues and analogs of which the prototype is the endogenous fatty acid ethanolamide, oleoylethanolamide. | 01-01-2009 |
| 20090023807 | Treatment of Cytokine Dysregulation by Using Sn-2 Gamma-Linolenoyl, Gamma-Diho-Molinolenoyl or Arachidonoyl Patty Acid Glycerol Monoesters - A method of treating a patient in need of therapy for a cytokine dysregulation comprising administering to that patient a therapeutically effective dose of a monoglyceride or metabolic precursor thereof of general formula (I), wherein R | 01-22-2009 |
| 20090023808 | Production and Purification of Esters of Polyunsaturated Fatty Acids - The present invention includes methods for producing and purifying esters of polyunsaturated fatty acids that include reacting a composition having triglycerides with polyunsaturated fatty acid residues in the presence of an alcohol and a base to produce an ester of a polyunsaturated fatty acid from the triglycerides. The composition can be a polyunsaturated fatty acid-containing composition that has not been conventionally processed. The reacted composition can be further processed by distillation. | 01-22-2009 |
| 20090131520 | Lipid metabolism Improving Composition - Disclosed is a composition for improving lipid metabolism. The composition for improving lipid metabolism comprises a fatty acid menthol ester as an active ingredient. | 05-21-2009 |
| 20090156673 | ANTI-INFLAMMATORY ACTIONS OF NEUROPROTECTIN D1/PROTECTIN D1 AND IT'S NATURAL STEREOISOMERS - (Neuro)protectin D1 (1OR,17S-dihydroxy-docosa-4Z,7Z,11E,13E,15Z,19Z-hexaenoic acid) and 15,16-dehydro-PD1 and their derivatives are useful in the treatment of airway inflammation, especially asthma. | 06-18-2009 |
| 20090203778 | FATTY ACID ANALOGUES, I.E. INCLUDING DHA DERIVATIVES FOR USES AS A MEDICAMENT - A compound of formula (I) wherein R | 08-13-2009 |
| 20090203779 | ESTERS OF LONG-CHAIN ALCOHOLS AND PREPARATION THEREOF - Disclosed is a composition and methods of treating a skin condition. The ester includes an ester and a dermatologically acceptable carrier. The ester is represented by the general formula 1: | 08-13-2009 |
| 20090203780 | Use of a Polyunsaturated Fatty Acid Compound - A polyunsaturated fatty acid having 20 carbon atoms and four double bonds, or a derivative thereof, in an orally administrable form, can be used to treat or prevent obesity and/or for weight management. The polyunsaturated fatty acid may, for example, be used in the form of a food supplement, a pharmaceutical composition or a food composition. | 08-13-2009 |
| 20090281182 | AGENT FOR AMELIORATION OF DYSPHAGIA, AND PHARMACEUTICAL OR FOOD COMPOSITION COMPRISING THE SAME - Disclosed is an agent for ameliorating dysphagia containing capsinoid as an active ingredient. Also disclosed is a pharmaceutical composition or food composition containing the agent. The agent, pharmaceutical composition or food can be administered to a subject suffering from dysphagia such as elderly person. | 11-12-2009 |
| 20090292019 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF - There are provided various polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds can be useful as cancer chemopreventive agents, cancer treating agent, inhibiting tumor growth or cell proliferation, reducing tumor growth or as radioenhencers for radiotherapy of cancer. | 11-26-2009 |
| 20090318553 | Use Of Docosahexaenoic Glycerides For The Treatment Of Tumorous Diseases - The present invention relates to the use of an oil enriched in docosahexaenoic acid, which is conjugated to triglyceride, for manufacturing a pharmaceutical composition for the treatment of a tumorous disease, said oil being enriched in a concentration of up to 70% by weight in relation to the total weight of said pharmaceutical composition, and said docosahexaenoic acid being in a percentage of at least 50% in relation to the total fatty acids in said oil. | 12-24-2009 |
| 20100010087 | Methods for Inducing Stem Cell Migration and Specialization with EC-18 - The present invention relates to promoting stem cell migration and specialization by administering one or more MADG compounds. The present invention further pertains to repairing or promoting the healing of injured tissue or a wound of an individual by administering a MADG compound (e.g., EC-18) to the individual, or subjecting the injured tissue/wound to a MADG compound. Another aspect of the invention relates to treating disease or conditions that benefit from stem cell therapy by administering MADG with or without exogenous stem cells. | 01-14-2010 |
| 20100016428 | USE OF POLYUNSATURATED FATTY ACIDS FOR THE PRIMARY PREVENTION OF MAJOR CARDIOVASCULAR EVENTS - The use of polyunsaturated fatty acids of the ω-3 series such as eicosapentaenoic acid (EPA, C | 01-21-2010 |
| 20100087526 | INHIBITORS OF POLYISOPRENYLATED METHYLATED PROTEIN METHYL ESTERASE - Inhibitors of the enzyme prenylated methylated protein methyl esterase (PMPMEase), the last step in the prenylation process for many eukaryotic proteins, having the general structure R | 04-08-2010 |
| 20100093857 | AMIDO-AMINE POLYMER COMPOSITIONS - Compounds, polymers, crosslinked polymers and pharmaceutical compositions comprising the same may be derived from multi-amine monomers and multi-functional monomers having two or more amine reactive groups. Such compounds, polymers, crosslinked polymers and compositions may be used to treat hyperphosphatemia or to remove ions from the gastrointestinal tract of animals, including humans. | 04-15-2010 |
| 20100130608 | COMPOSITIONS AND METHODS FOR REDUCING TRIGLYCERIDE LEVELS - The present invention is directed to methods of reducing plasma triglyceride level in subjects by administering docosahexaenoic acid (DHA). The method can comprise administering daily to the subject a dosage form comprising docosahexaenoic acid ester substantially free of eicosapentaenoic acid (EPA), wherein the DHA is derived from an algal source. In some embodiments, the method comprises administering daily to the subject a dosage form comprising DHA ester substantially free of EPA, wherein the DHA ester is about 60% to about 99.5% (w/w) of the total fatty acid content of the dosage form. In some embodiments, the method comprises administering daily to the subject a dosage form comprising about 200 mg to about 4 g of DHA ester substantially free of EPA. In some embodiments, the foregoing methods also result in a lowering of the amount of total cholesterol in the subject. | 05-27-2010 |
| 20100144876 | MODULATOR - The present invention relates to a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein Z is OR | 06-10-2010 |
| 20100216882 | ASPIRIN-TRIGGERED LIPID MEDIATORS - Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with diseases, including ischemia. | 08-26-2010 |
| 20100216883 | METHOD OF USING ABSCISIC ACID TO TREAT AND PREVENT DISEASES AND DISORDERS - Methods and compositions for treating inflammatory bowel disease, gastrointestinal inflammation and maintaining normal gut health are described. These methods of the invention involve the administration of abscisic acid in amounts sufficient to alter the expression or activity of PPAR gamma in a cell. Also described are methods for suppressing the expression of cellular adhesion molecules in the gut and methods for increasing CTLA-4 expression on CD4+ T cells through administration of abscisic acid. | 08-26-2010 |
| 20100267828 | DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS - The present disclosure relates to compounds of the general formula (I): | 10-21-2010 |
| 20100273878 | PREVENTIVE OR THERAPEUTIC DRUG FOR ALZHEIMER-TYPE DEMENTIA - It is intended to provide a highly safe preventive or therapeutic drug for Alzheimer-type dementia which can replace the conventional therapies currently used for Alzheimer-type dementia or which can be used together with the conventional therapy to realize high therapeutic effects, characterized in that a ω-3 polyunsaturated fatty acid and thyroid hormone are used in combination. | 10-28-2010 |
| 20100305205 | COMPOSITION AND/OR METHOD FOR PREVENTING RECURRENCE OF STROKE - By using a composition for preventing onset and/or recurrence of stroke which contains ethyl icosapentate as its effective component, onset and/or recurrence of stroke is prevented, or in particular, the onset and/or recurrence of stroke in a hyperlipidemia patient who has been treated with HMG-CoA RI, or in particular the recurrence of stroke in a patient who is beyond six months after the onset of stroke, is prevented. | 12-02-2010 |
| 20110028547 | NOVEL USE OF CAPSIATE OR DIHYDROCAPSIDATE - The present invention relates to a new use of capsiate or dihydrocapsiate, more particularly to a composition for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease or for suppressing immunity comprising capsiate, dihydrocapsiate or a pharmaceutically acceptable salt thereof as an effective ingredient. The composition and immunosuppressant of the present invention may be used for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease, and for suppressing immunity. | 02-03-2011 |
| 20110034555 | COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISING LDL-C LEVELS IN A SUBJECT ON CONCOMITANT STATIN THERAPY - In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. | 02-10-2011 |
| 20110039928 | Cetylated fatty acid and alkali buffered creatine anti-inflammatory composition - An anti-inflammatory composition for treatment of inflamed joints. This composition includes an alkali buffered creatine and a cetylated fatty acid. The composition can be used for treating inflammation either by oral ingestion or by topical treatment. | 02-17-2011 |
| 20110077301 | NOVEL METHODS OF ADMINISTERING A MIXTURE OF FATTY ACIDS FOR THE TREATMENT OF NON-HUMAN MAMMALS - Mixture of fatty acids, their derivatives, ester or methyl ester derivates thereof, which may be administered to non-human mammals by diffusion in to ambient air during at least seven consecutive days, with a rapid kinetic of diffusion during the first three days of administration. | 03-31-2011 |
| 20110082205 | Docosahexaenoic Acid Gel Caps - The present invention is directed to an oral dosage form comprising a gel capsule comprising, (a) plasticizer; (b) gelatin; (c) water; and (d) greater than 850 mg DHA ethyl ester, wherein less than about 2% (wt/wt) of the total fatty acid content of the dosage form is EPA, wherein the total weight of the capsule is about 1 g and wherein the capsule is stable at about 25° C. at 60% relative humidity. | 04-07-2011 |
| 20110086914 | Methods for Treating Traumatic Brain Injury - The present disclosure provides methods of treating traumatic brain injury. | 04-14-2011 |
| 20110092592 | DIAGNOSIS AND TREATMENT OF HEPATIC DISORDER - Disclosed is a diagnosis or treatment method which utilizes the content of a specific fatty acid in plasma as a marker that reflects the condition of NASH or NAFLD, or utilizes the above-mentioned content in combination with another test, another marker or the like. | 04-21-2011 |
| 20110098356 | Production and Purification of Esters of Polyunsaturated Fatty Acids - The present invention includes methods for producing and purifying esters of polyunsaturated fatty acids that include reacting a composition having triglycerides with polyunsaturated fatty acid residues in the presence of an alcohol and a base to produce an ester of a polyunsaturated fatty acid from the triglycerides. The composition can be a polyunsaturated fatty acid-containing composition that has not been conventionally processed. The reacted composition can be further processed by distillation. | 04-28-2011 |
| 20110105609 | ALLEVIATING OXIDATIVE STRESS DISORDERS WITH PUFA DERIVATIVES - Some aspects of the invention provide for essential fatty acids which are substituted in specific positions to slow down oxidative damage by Reactive Oxygen Species (ROS), and to suppress the rate of consequent formation of reactive products, for the purpose of preventing or reducing the damage associated with oxidative stress associated diseases such as neurological diseases and age-related macular degeneration (AMD). | 05-05-2011 |
| 20110118350 | COMPOSITION FOR PREVENTING CARDIOVASCULAR EVENT IN HIGH-RISK PATIENT - Provided is a pharmaceutical composition for reducing the risk in a patient at high risk for occurrence and/or recurrence of a cardiovascular event by administering the composition to the patient with a high ratio of oleic acid to stearic acid in plasma. The pharmaceutical composition contains ethyl icosapentate as its effective component. The composition is expected to reduce the risk in the patient at high risk for occurrence and/or recurrence of a cardiovascular event, and particularly to have a preventive effect on occurrence and/or recurrence of a cardiovascular event in the patient with a high ratio of oleic acid to stearic acid in plasma. | 05-19-2011 |
| 20110130457 | Wax-Based Emulsion for the Treatment of Dry Eye Conditions - Disclosed herein is a wax-based emulsion for the treatment of dry eye conditions by reducing the evaporation rate of saline and increasing the viscosity of the tear film. The composition of the present invention comprises an emulsion of wax dispersed in saline. One embodiment of the wax-based emulsion of the present invention comprises a wax in an amount ranging from about 0.001% to about 80% by weight and the remainder saline. In another embodiment, the wax-based emulsion further comprises a hydrocarbon in an amount ranging from about 0.01% to about 80% by weight. In still another embodiment, the wax-based emulsion of the present invention further comprises a cholesterol ester ranging in an amount from about 0.01% to about 80% by weight. In an alternative embodiment, the wax-based emulsion of the present invention further comprises an opthalmic drug in an amount ranging from about 0.01% to about 80% by weight. In yet another embodiment, the wax based emulsion comprises a wax in an amount ranging from about 40% to about 60% by weight, a cholesterol ester in an amount ranging from about 10% to about 20% by weight and the remainder saline. The wax based emulsion may further comprise a hydrocarbon in an amount of up to about 20% by weight. In yet another embodiment, the emulsion further comprises an amount ranging between about 1% to about 20% by weight of standard opthalmic drugs such as antibiotics for delivery to the eye. In some embodiments, the wax of the emulsion is a synthetic wax. | 06-02-2011 |
| 20110172305 | Endocannabinoids for Enhancing Growth and Development in Infants - The present invention relates to a method for promoting infant feeding, growth or development comprising administering to an infant a formula or a pharmaceutical composition comprising an endocannabinoid in an amount sufficient to promote feeding, growth or development. The present invention also relates to an infant formula comprising an enhanced amount of an endocannabinoid. The infant formula of the invention may be in a powder form or in a liquid form. The infant formula or the pharmaceutical composition may further comprise an endocannabinoid-promoting compound. | 07-14-2011 |
| 20110201682 | MIXTURE OF FATTY ACID ESTERS OF NATURAL ORIGIN AND ITS USE IN COSMETIC PREPARATIONS BASED ON OLIVE OIL DERIVATIVES - Mixture comprising esters of saturated C | 08-18-2011 |
| 20110213031 | NOVEL TYPE I NATURAL CERAMIDE DERIVATIVE AND METHOD FOR PRODUCING SAME - The present invention aims to provide a novel type I natural ceramide derivative having a structure more similar to that of a type I natural ceramide composed of sphingosine and an ω-acyloxy long-chain carboxylic acid; and a method for producing the same. The derivative is provided by reacting an ω-acyloxy long-chain fatty acid derivative with dihydrosphingosine or a salt thereof. The thus produced novel type I natural ceramide derivative, when combined with other ceramides, can significantly improve the compatibility of ceramides, which facilitates preparation of a composition containing ceramides, such as a moisturizer or a cosmetic, and also increases the storage stability of the composition. | 09-01-2011 |
| 20110218243 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE - In various embodiments, the present invention provides pharmaceutical compositions comprising fatty acids and methods for treating subjects using same. | 09-08-2011 |
| 20110224298 | DIENE COMPOUNDS FOR USE IN HUMAN EPIDERMAL CELL REPAIR AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM - The present invention relates to a novel use of compounds having the general formula (I): | 09-15-2011 |
| 20110230557 | POLYUNSATURATED FATTY ACID AND DIOL ESTER AS AN ANTI-ACNE AGENT - The present invention relates to compounds of the following formula (I): where n is an integer between 1 and 15, m is 0, 1, 2 or 3, and R is the hydrocarbon chain of a polyunsaturated fatty acid selected from among omega 3 and omega 6, as well as to pharmaceutical or cosmetic compositions containing same, to a method for preparing and using same, in particular for treating acne and seborrhoeic dermatitis. | 09-22-2011 |
| 20110251276 | BIOLOGICAL OIL COMPOSITION, FORMULATIONS COMPRISING THE OIL COMPOSITION, AND USE THEREOF TO PREVENT OR TREAT CARDIOVASCULAR DISEASE - This invention relates to a biological oil composition, preferably obtained from a copepod, most preferably the copepod | 10-13-2011 |
| 20110288171 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 11-24-2011 |
| 20120016024 | Water-In-Oil Emulsion Composition - The present invention provides a water-in-oil emulsion composition that provides a post-application elastic feeling, softness, and a moisturizing effect and that is excellent in emulsion stability while it is a composition with a high internal-aqueous-phase proportion, which allows the makeup to stay on nicely because of its uniform applicability and provides a refreshing effect on the skin when used as a pre-makeup emulsion. The water-in-oil emulsion composition of the present invention is characterized by comprising the below-described components (A) (B) and (C), and satisfying the below-described conditions (1) and (2). Components: (A) glycerol isostearate and/or glycerol oleate, (B) an aqueous component, (C) an oil component containing an isoparaffin having 20 carbon atoms or less. Conditions: (1) The internal-aqueous-phase proportion, which is obtained by dividing the mass of the aqueous component (B) by the sum of the mass of the aqueous component (B) and the mass of the oil component (C), is 68% or higher, (2) The amount of glycerol monoisostearate and/or glycerol monooleate contained in component (A) is 85 mass % or higher with respect to the total amount of (A). | 01-19-2012 |
| 20120035262 | COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES - In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. | 02-09-2012 |
| 20120041064 | SKIN TREATMENT - The present invention relates generally to the cosmetic treatment of aged skin. More specifically, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in treating photo-aged and/or chronologically-aged skin. | 02-16-2012 |
| 20120065260 | NOVEL COMPOUNDS - Compounds of formula (I); | 03-15-2012 |
| 20120108659 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 05-03-2012 |
| 20120108660 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 05-03-2012 |
| 20120129934 | METHODS FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER'S TYPE - The present invention relates to the diagnosis, risk assessment, prevention, and treatment of Senile Dementia of the Alzheimer's Type (SDAT). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum. Subsets of these molecules are significantly altered in subjects with pathologically confirmed deposits of β-amyloid versus subjects without β-amyloid deposits and in subjects with a clinical manifestation of dementia consistent with a diagnosis of SDAT versus non-demented controls. Further, the invention relates to the diagnosis of various stages of SDAT, the early detection and prevention of SDAT symptoms, the treatment of SDAT, the differential diagnosis of non-SDAT dementia, and the identification of molecular targets for which chemical or biological treatments can be designed for the therapeutic intervention of SDAT. The present invention also relates to methods of using a molecular diagnostic assay to direct and select the appropriate therapeutic intervention for subjects suffering from dementia. The present invention also relates to small molecules or metabolites that are found to have significantly different abundances between persons with a clinical manifestation of SDAT and normal, non-demented patients. | 05-24-2012 |
| 20120136053 | COPEPOD OIL COMPOSITION, FORMULATIONS COMPRISING THE OIL COMPOSITION, AND THE USE THEREOF TO REDUCE ACCUMULATION OF VISCERAL FAT, IMPROVE GLUCOSE TOLERANCE, AND PREVENT OR TREAT OBESITY RELATED DISEASES AND DISORDERS - This invention relates to an oil composition, preferably obtained from a copepod, and the use thereof to reduce accumulation of visceral fat and counteract impairment of heart function caused by obesity inducing Western diets. The oil composition of the present invention can thus be used to reduce abdominal obesity and improve glucose tolerance and thus to reduce the risk of obesity related diseases such as but not limited to type 2 diabetes or cardiovascular disease, or to prevent or treat such diseases. | 05-31-2012 |
| 20120142774 | EMULSIFYING PREPARATION - An emulsifying preparation for an oil-soluble component, which is sensorily superior when applied to an aqueous phase, can maintain stability for a long time, and imposes less restriction for formulation or production is provided. The emulsifying preparation of the present invention contains (A) an oil phase component containing an oil-soluble component, (B) an aqueous phase component containing a polyol, and (C) an emulsifier containing polyglycerol fatty acid monoester having an average degree of polymerization of not less than 10, and having an HLB value of not less than 14 and not more than 18 or showing a transmittance of 1 wt % aqueous solution at 600 nm of not less than 80%. | 06-07-2012 |
| 20120142775 | TREATMENT OF NEURODEGENERATIVE CONDITIONS - A method is provided for treating a patient in need of therapy for a neurodegenerative disease comprising administering to that patient a therapeutically effective dose of a lipid glyceride comprising a glycerol moiety and a fatty acid moiety, the fatty acid moiety being selected from the group consisting of γ-linolenic acid, dihomo-γ-linolenic acid and arachidonic acid characterised in that the selected fatty acid moiety is attached to the glycerol moiety at its sn-2 position. Preferably the method is that wherein the lipid is administered for a duration and at a dose sufficient to maintain or elevate TGF-β1 levels in the patient to therapeutic levels. | 06-07-2012 |
| 20120172431 | OMEGA 3 FATTY ACID FORMULATIONS - The present invention provides highly purified omega-3 fatty acid formulations. Certain formulations provided herein have contain greater than 85% omega-3 fatty acids by weight. Certain other formulations provided herein contain EPA and DHA in a ratio of from about 4.01:1 to about 5:1. The invention also provides methods of using the dosage forms to treat a variety of cardiovascular, autoimmune, inflammatory, and central nervous system disorders by administering a formulation of the invention to a patient in need thereof. | 07-05-2012 |
| 20120172432 | PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND A CARDIOVASCULAR AGENT AND METHODS OF USING THE SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising EPA and one or more cardiovascular agents, and to therapeutic methods for treating various diseases and disorders using the same. | 07-05-2012 |
| 20120208884 | COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES THEREOF AND USES THEREOF - There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability. | 08-16-2012 |
| 20120225941 | COMPOSITIONS AND METHODS COMPRISING C16:1n7-PALMITOLEATE - One embodiment described herein is related to methods and compositions, such as nutraceutical formulations and dietary supplements, comprising C16:1n7-palmitoleate or derivatives thereof. The methods and compositions comprising C16:1n7-palmitoleate, or derivatives thereof, safely and effectively prevent or mitigate manifestations of cardiovascular disease, including coronary artery disease and the accumulation of cholesterol or lipid deposits in the blood vessels of a subject. | 09-06-2012 |
| 20120232143 | LIPID DERIVATIVES - The present invention relates to lipid compounds of the general formula (I): wherein —R | 09-13-2012 |
| 20120264824 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS - Methods and compositions are disclosed comprising ethyl eicosapentanoate for the treatment of non-alcoholic steatohepatitis (NASH). | 10-18-2012 |
| 20120270944 | ANTIOXIDANTS AND VEGETABLE OILS AS STABILIZERS OF INSECT SEMIOCHEMICALS - Semiochemicals are combined with oils and/or antioxidants in order to control and maintain the necessary threshold release rates of the semiochemicals (such as attractants or repellents) from release devices for optimal activity/performance, for the reduction or elimination of semiochemical oxidation, isomerization, breakdown and polymerization, and also for stabilizing and/or protecting the active semiochemical ingredients. | 10-25-2012 |
| 20120277317 | USE OF A FATTY ACID COMPOSITION CONTAINING DHA FOR THE PRODUCTION OF A MEDICAL PRODUCT OR A FOOD STUFF FOR THE TREATMENT OF AMYLOIDOS-RELATED DISEASES - A method for the treatment and/or prevention of amyloidos-related diseases, such as for example Alzheimer's disease and IgA nephropathy, comprising administering to a human or an animal a composition comprising at least (all-Z omega-3)-4,7,10,13,16,19-docosahexaenoic acid (DHA) is provided. | 11-01-2012 |
| 20120316237 | Pest Control Composition - It is an object of the present invention to provide a pest control composition capable of exerting a high effect on pests such as spider mites and aphids even at low concentration using a food/food additive with high safety to the human body and the environment. The present inventors have intensively studied to solve the above problem and found that, among polyglycerol fatty acid esters widely used as a food additive, a composition containing a polyglycerol fatty acid ester which has an HLB of 5 or less and is liquid at ordinary temperature and also a nonionic surfactant has a high effect on pests even at low concentration, and that the possibility for pests to develop resistance to the composition is extremely low, and the present invention has been completed. | 12-13-2012 |
| 20130005809 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 01-03-2013 |
| 20130012580 | COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES WITHOUT RAISING LDL-C LEVELS IN A SUBJECT ON CONCOMITANT STATIN THERAPY - In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. | 01-10-2013 |
| 20130046016 | METHOD FOR LOWERING CHOLESTEROL - The present invention relates to a method of lowering cholesterol in a patient in need thereof by administering to said patient a therapeutic effective amount of a compound selected from the group of Dihydroxyacetone phosphate (DHAP); 1-acyl-DHAP; 1-alkyl-DHAP; 1-alkyl-glyceraldehyde-3-phosphate (G3P); 1-alkyl, 2-acyl-G3P; 1-alkyl, 2-acyl-glycerol; 1-alkyl,2-acyl-glycerylphosphatidylethanolamine (GPE), 1-alkyl, diacyl glycerol (sn-1=16:0, sn-2=docosohexaenoic acid (DHA); sn-3=DHA) (sn-1 position has an alkyl ether bond, sn-2 and sn-3 positions have acyl bonds); 1-alkyl diacyl glycerol (sn-1=16:0, sn-2=18:1, sn-3=18:1) (sn-1 position has an alkyl ether bond, sn-2 and sn-3 positions have acyl bonds); triacyl glycerol (sn-1=16:0, sn-2=DHA, sn-3=DHA) (all three positions have acyl bonds); and triacyl glycerol (sn-1=16:0, sn-2=18:1, sn-3=18:1) (all three positions have acyl bonds) and pharmaceutically acceptable salts thereof. | 02-21-2013 |
| 20130059911 | POLYUNSATURATED FATTY ACID MONOGLYCERIDES, DERIVATIVES, AND USES THEREOF - There are provided various polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds can be useful as cancer chemopreventive agents, cancer treating agent, inhibiting tumor growth or cell proliferation, reducing tumor growth or as radioenhencers for radiotherapy of cancer. | 03-07-2013 |
| 20130065956 | COMPOSITION AND/OR METHOD FOR PREVENTING ONSET AND/OR RECURRENCE OF CARDIOVASCULAR EVENTS - Provided are composition and/or methods useful in preventing onset and/or recurrence of cardiovascular events, especially in patients who have escaped the unstable period after cardiovascular angioplasty or in hyperlipidemia patients who have been treated with HMG-CoA RI. | 03-14-2013 |
| 20130131170 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 05-23-2013 |
| 20130131171 | Treatment for Meibomian Gland Dysfunction or Obstruction - A jojoba formulation has been developed for administration to the meibomian gland, for treatment of the symptoms of dry eye, and/or for drug delivery to the meibomian gland. The formulation incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear as well as stabilize the tear film. The jojoba wax tear relieves irritation and discomfort as well as sharpens the blurred vision. Jojoba, because of its close chemical and physical properties to meibomian gland secretions, is effective upon topical application to penetrate the lid margin to reach the gland tissues where it may exert a therapeutic effect with or without an adjunctive agent. | 05-23-2013 |
| 20130137767 | Methods and Compositions for Treating Arthritis with Docosahexaenoic Acid - The present invention is directed to methods and compositions for treating arthritis in a subject, comprising administering about 430 mg to about 12.4 g of docosahexaenoic acid (DHA) per day in a dosage form to the subject in need thereof, wherein the dosage form is substantially free of eicosapentaenoic acid (EPA) and substantially free of non-alpha tocopherol. | 05-30-2013 |
| 20130137768 | PANTHENYL DOCOSAHEXAENEOATE AND ITS USE FOR TREATING AND PREVENTING CARDIOVASCULAR DISEASES - The present invention relates to the docosahexaenoatepanthenyl of the following formula: It also relates to a method for preparing same and to a pharmaceutical composition comprising same and to the use of same in the treatment or the prevention of cardiovascular diseases, in particular atrial fibrillation. | 05-30-2013 |
| 20130150443 | DIENE COMPOUNDS FOR USE IN HUMAN EPIDERMAL CELL REPAIR, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM - The present invention relates to a novel use of compounds having the general formula (I): | 06-13-2013 |
| 20130165513 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 06-27-2013 |
| 20130165514 | ORALLY ADMINISTERED COMPOSITION AND DIETARY COMPOSITION HAVING SERUM LIPID IMPROVING EFFECT - The present invention provides an orally administered composition and a dietary composition, which have a serum lipid improving effect. The orally administered composition and dietary composition, having a serum lipid improving effect, according to the present invention camp rise 2.0% by weight or less of a DHA ethyl ester composition comprising 75% by weight or more of DHA ethyl ester. It is preferable to comprise 1.2% by weight or less of the DHA ethyl ester composition. It is preferable not to substantially comprise a DHA ethyl ester composition comprising 30% by weight or less of DHA ethyl ester. | 06-27-2013 |
| 20130172412 | Methods for Improving Cognitive Function and Decreasing Heart Rate - The present invention is directed to methods of improving cognitive function in subjects having age related cognitive decline or mild cognitive impairment and to methods of decreasing heart rate in a subject by administering dosage forms comprising docosahexaenoic acid (DHA) substantially free of eicosapentaenoic acid (EPA). | 07-04-2013 |
| 20130172413 | STABLE PHARMACEUTICAL COMPOSITION AND METHODS OF USING SAME - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 07-04-2013 |
| 20130245117 | NOVEL USE OF CAPSIATE OR DIHYDROCAPSIDATE - The present invention relates to a new use of capsiate or dihydrocapsiate, more particularly to a composition for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease or for suppressing immunity comprising capsiate, dihydrocapsiate or a pharmaceutically acceptable salt thereof as an effective ingredient. The composition and immunosuppressant of the present invention may be used for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease, and for suppressing immunity. | 09-19-2013 |
| 20130253057 | Personal Care Compositions and Methods - A personal care composition includes a cleansing phase and a benefit phase, the cleansing phase having a surfactant and the benefit phase having a lipid bilayer structurant. Methods to enhance skin hydration are also provided. | 09-26-2013 |
| 20130274333 | CORIOLUS VERSICOLOR EXTRACTS, METHODS OF ISOLATING BIOLOGICALLY-ACTIVE COMPOUNDS, AND USES THEREOF - The subject invention provides efficient and convenient methods of isolating 9-oxo-10E, 12E-octadecadienoic acid methyl ester (9-KODE methyl ester) from | 10-17-2013 |
| 20130296425 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR A PERIPHERAL NERVE DISORDER INDUCED BY ANTI-CANCER AGENTS - An object of the present invention is to provide a drug which is effective for prophylaxis or therapy of peripheral nerve disorder occurred as a side effect of the administration of anti-cancer agents. | 11-07-2013 |
| 20130324607 | METHODS OF TREATING HYPERCHOLESTEROLEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of treating hypercholesterolemia, comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 12-05-2013 |
| 20130331447 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 12-12-2013 |
| 20130338226 | INGENOLS FOR TREATING SEBORRHEIC KERATOSIS - The invention provides ingenol compounds for treating seborrheic keratosis. | 12-19-2013 |
| 20140005264 | METHODS OF TREATING PEDIATRIC METABOLIC SYNDROME | 01-02-2014 |
| 20140031426 | SN-1(3) MONOACYLGLYCERIDES AND LIPID ABSORPTION - The present invention relates generally to the field of lipids and in particular aims at improving lipid absorption, for example under conditions of lipid maldigestion or malabsorption. One embodiment of the present invention relates to a composition comprising sn-1(3) monoacylglycerols, wherein the sn-1 or sn-3 position is occupied by an acyl group such as a fatty acid and the sn-2 position remains unoccupied. The fatty acid may be one with anti-inflammatory properties. | 01-30-2014 |
| 20140057981 | SELF-EMULSIFYING COMPOSITION OF OMEGA3 FATTY ACID - This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug. | 02-27-2014 |
| 20140100272 | METHODS OF ADMINISTERING COMPOSITIONS COMPRISING DOCOSAPENTAENOIC ACID - The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid. | 04-10-2014 |
| 20140100273 | METHODS OF ADMINISTERING COMPOSITIONS COMPRISING DOCOSAPENTAENOIC ACID - The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid. | 04-10-2014 |
| 20140100274 | METHODS OF ADMINISTERING COMPOSITIONS COMPRISING DOCOSAPENTAENOIC ACID - The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid. | 04-10-2014 |
| 20140100275 | METHODS OF ADMINISTERING COMPOSITIONS COMPRISING DOCOSAPENTAENOIC ACID - The present invention relates to compositions comprising docosapentaenoic acid and methods of reducing lipid parameters, such as triglycerides, total cholesterol, low density lipoprotein (LDL) cholesterol, non-HDL cholesterol, free fatty acids, and other lipids, comprising administration of omega-3 docosapentaenoic acid. | 04-10-2014 |
| 20140107198 | OMEGA-3 PENTAENOIC ACID COMPOSITIONS AND METHODS OF USE - Orally administrable composition comprising fatty acids, wherein at least 50% by weight of the fatty acids comprise omega-3-fatty acids, salts or derivatives thereof, wherein the omega-3 fatty acids comprise eicosapentaenoic acid (EPA; C20:5-n3), docosapentaenoic acid (DPA; C22:5-n3), and docosahexaenoic acid (DHA; C22:6-n3), wherein the ratio of DHA to EPA (DHA:EPA) is less than 1:20, and wherein the ratio of DHA to DPA (DHA:DPA) is less than 2:1 are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore. | 04-17-2014 |
| 20140107199 | OMEGA-3 PENTAENOIC ACID COMPOSITIONS AND METHODS OF USE - Orally administrable composition comprising fatty acids comprising omega-3-fatty acids, salts or derivatives thereof are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore. | 04-17-2014 |
| 20140107200 | OMEGA-3 PENTAENOIC ACID COMPOSITIONS AND METHODS OF USE - Orally administrable composition comprising fatty acids comprising omega-3-fatty adds, salts or derivatives thereof are provided. These compositions can be used for the treatment or prophylaxis of dyslipidemic, cardiovascular, CNS, inflammatory, and other diseases/conditions or risk factors therefore. | 04-17-2014 |
| 20140128464 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE - In various embodiments, the present invention provides pharmaceutical compositions comprising fatty acids and methods for treating subjects using same. | 05-08-2014 |
| 20140128465 | PRODUCTION AND PURIFICATION OF ESTERS OF POLYUNSATURATED FATTY ACIDS - The present invention includes methods for producing and purifying esters of polyunsaturated fatty acids that include reacting a composition having triglycerides with polyunsaturated fatty acid residues in the presence of an alcohol and a base to produce an ester of a polyunsaturated fatty acid from the triglycerides. The composition can be a polyunsaturated fatty acid-containing composition that has not been conventionally processed. The reacted composition can be further processed by distillation. | 05-08-2014 |
| 20140155481 | COMPOSITIONS AND METHODS FOR LOWERING TRIGLYCERIDES IN A SUBJECT ON CONCOMITANT STATIN THERAPY - In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. | 06-05-2014 |
| 20140187633 | METHODS OF TREATING OR PREVENTING NONALCOHOLIC STEATOHEPATITIS AND/OR PRIMARY BILIARY CIRRHOSIS - In various embodiments, the present invention provides methods of treating and/or preventing NASH and/or PBC comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 07-03-2014 |
| 20140221486 | METHODS OF REDUCING APOLIPOPROTEIN C-III - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 08-07-2014 |
| 20140235715 | TASTE MASKING FORMULATIONS OF FATTY ACIDS - Methods and formulations for improving the sensory characteristics and stability of dietary fatty acids for use in beverages, liquid concentrates, or other formulations are disclosed. | 08-21-2014 |
| 20140249220 | COMPOSITIONS AND METHODS FOR REDUCING A FATTY ACID DESATURATION INDEX IN A SUBJECT IN NEED THEREOF - In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof. | 09-04-2014 |
| 20140256809 | COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND A HYDROXYL COMPOUND AND METHODS OF USE THEREOF - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases. | 09-11-2014 |
| 20140275252 | METHODS OF TREATING TRAUMATIC BRAIN INJURY - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent traumatic brain injuries. | 09-18-2014 |
| 20140275253 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OBESITY IN A SUBJECT IN NEED THEREOF - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent obesity. | 09-18-2014 |
| 20140343143 | Use of highly concentrated compositions of selected n-3 fatty acids for the treatment of central nervous system disturbances - The use is described of a composition comprising either a) alpha-linolenic acid (ALA, C18:3 n-3) or b) docosahexaenoic acid (DHA, C22:6 n-3) or c) DHA in admixture with eicosapentaenoic acid (EPA, C20:5 n-3), in a ratio of 1:0.5 to 1:1.7, respectively, and/or the pharmaceutically acceptable derivatives and/or precursors thereof; either a) or b) or c) being in a concentration not lower than 70% by weight of the total fatty acids weight in the composition, for the preparation of a drug for the prevention and/or treatment of the disturbances of the central nervous system (CNS) such as epilepsy, schizophrenia, bipolar (manic-depressive illness) and unipolar (major depression) psychiatric disorders, and by degenerative Alzheimer's disease and related forms of dementia. | 11-20-2014 |
| 20140357717 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 12-04-2014 |
| 20140364499 | CORIOLUS VERSICOLOR EXTRACTS, METHODS OF ISOLATING BIOLOGICALLY-ACTIVE COMPOUNDS, AND USES THEREOF - The subject invention provides efficient and convenient methods of isolating 9-oxo-10E, 12E-octadecadienoic acid methyl ester (9-KODE methyl ester) from | 12-11-2014 |
| 20140371312 | COMPOSITION FOR PREVENTING THE OCCURRENCE OF CARDIOVASCULAR EVENT IN MULTIPLE RISK PATIENT - Disclosed is a composition which is useful for preventing the occurrence of a cardiovascular event, particularly a composition which is expected to show a prophylactic effect on a cardiovascular event occurring in a hypercholesterolemia patient despite providing the patient with a treatment with HMG-CoA RI or a cardiovascular event occurring in a multiple risk patient. | 12-18-2014 |
| 20140378543 | METHODS OF PRODUCING AND USING NUTRITIONAL AND PHARMACEUTICAL COMPOSITIONS THAT INCLUDE ONE OR MORE ACTIVE SUBSTANCES - Methods for producing a composition that includes an active agent, nutraceutical and pharmaceuticals compositions, and methods for ameliorating and/or treating a disease using the composition that includes an active substance are described herein. More particularly, methods for producing a composition that contains one or more active substances such as oleocanthal, pharmaceutical compositions that include one or more active substances such as oleocanthal, and methods of ameliorating and/or treating inflammation using compositions that contains one or more active substances such as oleocanthal are described. | 12-25-2014 |
| 20150011631 | Cetylated fatty acid and alkali buffered creative anti-inflammatory composition - An anti-inflammatory composition for treatment of inflamed joints. This composition includes an alkali buffered creatine and a cetylated fatty acid. The composition can be used for treating inflammation either by oral ingestion or by topical treatment. | 01-08-2015 |
| 20150045431 | METHODS OF TREATING A CARDIOVASCULAR DISORDER IN A SUBJECT ON APO-C3 MODULATING THERAPY - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on Apo-C3 modulating therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 02-12-2015 |
| 20150051282 | METHODS OF TREATING A CARDIOVASCULAR DISORDER AND/OR JOINT PAIN IN A SUBJECT ON GLUCOSAMINE THERAPY - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on glucosamine therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 02-19-2015 |
| 20150057347 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION AND LIPID DISORDERS - The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammation and lipid disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hypertriglyceridemia, steatohepatitis, cystinosis and inflammatory diseases. | 02-26-2015 |
| 20150057348 | METHODS FOR TREATING INFLAMMATORY DISEASES WITH COMPOSITIONS COMPRISING POLYUNSATURATED FATTY ACID MONOGLYCERIDES OR DERIVATIVES THEREOF - There are provided methods for treating an inflammatory diseases chosen from inflammatory bowel diseases, asthma, acute respiratory distress syndrome, chronic obstructive pulmonary disease, acute lung injury, bronchopulmonary dysplasia, cystic fibrosis, bronchitis, bronchiolitis, arthritis, osteoarthritis, ankylosing spondylitis and rheumatism. The method comprise administering to a subject in need thereof an effective amount of at least one lipid and an effective amount of at least one compound chosen from compounds of the present disclosure. Such compounds are polyunsaturated fatty acid monoglycerides or derivatives thereof. | 02-26-2015 |
| 20150065572 | METHODS OF TREATING OR PREVENTING PROSTATE CANCER - In various embodiments, the present invention provides methods of treating and/or preventing prostate cancer and, in particular, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 03-05-2015 |
| 20150073050 | CO-ADMINISTRATION OF OMEPRAZOLE AND EICOSAPENTAENOIC ACID OR A DERIVATIVE THEREOF - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing triglycerides in a subject on omeprazole therapy, the method comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 03-12-2015 |
| 20150111966 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FIBROMYALGIA PAIN - The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of fibromyalgia pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, post herpetic neuralgia, diabetic neuropathy, bipolar depression, stress, cancer pain, and lower back pain. | 04-23-2015 |
| 20150119462 | 14-HYDROXY-DOCOSAHEXAENOIC ACID COMPOUNDS - The invention describes novel 14-hydroxy docosahexaenoic acid (DHA) analogues, their preparation, isolation, identification, purification and uses thereof. | 04-30-2015 |
| 20150126601 | LIQUID COMPOSITIONS COMPRISING A SUSPENDED INSECT GROWTH REGULATOR - Liquid compositions comprising suspended, solid insect growth regulators are disclosed. Processes for producing such liquid compositions and uses thereof in animal feeds are also disclosed. | 05-07-2015 |
| 20150141510 | CARDIOVASCULAR DISEASE PRIMARY PREVENTION AGENT FOR PATIENTS HAVING HIGH BLOOD LEVELS OF HIGH-SENSITIVITY C-REACTIVE PROTEIN - The present invention provides the following: a cardiovascular disease primary prevention agent, which comprises as the active ingredient at least one selected from the group consisting of EPA, salts thereof, and esters thereof and is for lowering the risk of cardiovascular disease by administration to subjects having a blood (serum or plasma) hs-CRP level of 1.0 mg/L or higher in spite of no history of cardiovascular disease; a combination marker comprising the blood hs-CRP value and serum EPA/AA ratio for evaluating the primary risk of cardiovascular disease in subjects having no history of cardiovascular disease; and a method for extracting subjects with high risk of cardiovascular disease and/or a method for preventing cardiovascular disease. | 05-21-2015 |
| 20150299117 | COMPOSITIONS AND METHODS FOR THE TREATMENT INFLAMMATION AND LIPID DISORDERS - The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing inflammation and lipid disorders may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of hypertriglyceridemia, steatohepatitis, cystinosis and inflammatory diseases. | 10-22-2015 |
| 20150306057 | METHOD FOR THE TREATMENT OF SENILE DEMENTIA OF THE ALZHEIMER'S TYPE - The present invention relates to the diagnosis, risk assessment, prevention, and treatment of Senile Dementia of the Alzheimer's Type (SDAT). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum. Subsets of these molecules are significantly altered in subjects with pathologically confirmed deposits of β-amyloid versus subjects without β-amyloid deposits and in subjects with a clinical manifestation of dementia consistent with a diagnosis of SDAT versus non-demented controls. Further, the invention relates to the diagnosis of various stages of SDAT, the early detection and prevention of SDAT symptoms, the treatment of SDAT, the differential diagnosis of non-SDAT dementia, and the identification of molecular targets for which chemical or biological treatments can be designed for the therapeutic intervention of SDAT. The present invention also relates to methods of using a molecular diagnostic assay to direct and select the appropriate therapeutic intervention for subjects suffering from dementia. The present invention also relates to small molecules or metabolites that are found to have significantly different abundances between persons with a clinical manifestation of SDAT and normal, non-demented patients. | 10-29-2015 |
| 20150328153 | STABLE MICELLES OF MIXED FATTY ACIDS - Described herein are compositions comprising at least one Omega-3 fatty acid ester and at least one surface active agent; wherein the compositions form micelles when in contact with an aqueous medium. Also provided is a method of administering to a subject a composition comprising at least one Omega-3 fatty acid ester and at least one surface active agent, wherein the at least one Omega-3 fatty acid ester forms micelles when in contact with an aqueous medium, and the bioavailability of the at least one Omega-3 fatty acid ester is substantially independent of a food effect. Said compositions are useful for treating cardiovascular conditions or disorders in a subject and for reducing side effects associated with the ingestion of Omega-3 fatty acid esters. Described are also various dosage forms for administering said compositions and use of said compositions in functional foods. Provided herein are also kits with instructions on how to administer said compositions. | 11-19-2015 |
| 20150342919 | METHOD FOR PREVENTING OR TREATING ALLERGIC DISEASE USING CAPSIATE OR SALT THEREOF - The present invention relates to a method for preventing, alleviating or treating allergic diseases using capsiate or a pharmaceutically acceptable salt thereof. Capsiate or a pharmaceutically acceptable salt thereof according to the present invention may be used for the purpose of preventing, alleviating or treating allergic diseases. | 12-03-2015 |
| 20150344402 | Omefibrates for Treating Dyslipidemia and Cardiovascular Disease - The present invention relates to the fibric acid derivatives of omega-3 fatty acids and their use in treating Type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic syndrome, cancer, Alzheimer's disease; and their use for modulating activity of peroxisome proliferator-activated receptors (PPARs). | 12-03-2015 |
| 20150359775 | METHODS OF REDUCING RLP-C - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 12-17-2015 |
| 20150366833 | Gel Compositions - Substantially anhydrous topical gel compositions comprising ingenol-3-angelate as a suspension in non-aqueous carriers. | 12-24-2015 |
| 20150374654 | LIPID COMPRISING DOCOSAPENTAENOIC ACID - The present invention relates to extracted plant lipid or microbial lipid comprising docosapentaenoic acid, and processes for producing the extracted lipid. | 12-31-2015 |
| 20160008311 | Oleacein For Treating Or Preventing Diseases Resulting From Atherosclerotic Plaques | 01-14-2016 |
| 20160015673 | METHOD FOR LOWERING CHOLESTEROL - The present invention relates to the diagnosis, risk assessment, prevention, and treatment of Senile Dementia of the Alzheimer's Type (SDAT). More specifically the present invention relates to the measurement of ethanolamine phospholipids in human serum. Subsets of these molecules are significantly altered in subjects with pathologically confirmed deposits of β-amyloid versus subjects without β-amyloid deposits and in subjects with a clinical manifestation of dementia consistent with a diagnosis of SDAT versus non-demented controls. Further, the invention relates to the diagnosis of various stages of SDAT, the early detection and prevention of SDAT symptoms, the treatment of SDAT, the differential diagnosis of non-SDAT dementia, and the identification of molecular targets for which chemical or biological treatments can be designed for the therapeutic intervention of SDAT. The present invention also relates to methods of using a molecular diagnostic assay to direct and select the appropriate therapeutic intervention for subjects suffering from dementia. The present invention also relates to small molecules or metabolites that are found to have significantly different abundances between persons with a clinical manifestation of SDAT and normal, non-demented patients. | 01-21-2016 |
| 20160030378 | COMPOSITIONS AND METHODS FOR TREATING NON-ALCOHOLIC STEATOHEPATITIS - The disclosure provides for a method for treating a fatty liver disease or disorder in a subject in need thereof, comprising selecting a subject having or suspected of having a fatty liver disease or disorder, wherein the subject is non diabetic, pre-diabetic, mildly diabetic; has normal or substantially normal biliary tract function; or has non or early stage hepatocyte apoptosis; and administering a therapeutically effective amount of a pharmaceutical composition comprising EPAs. | 02-04-2016 |
| 20160058729 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 03-03-2016 |
| 20160120837 | Methods of reducing apolipoprotein C-III - In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof. | 05-05-2016 |
| 20160143873 | GEL COMPOSITIONS - Substantially anhydrous topical gel compositions comprising ingenol-3-angelate as a suspension in non-aqueous carriers. | 05-26-2016 |
| 20160143875 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING OBESITY IN A SUBJECT IN NEED THEREOF - The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent obesity. | 05-26-2016 |
| 20160158184 | SELF-EMULSIFYING COMPOSITION OF OMEGA3 FATTY ACID - A self-emulsifying composition which comprises, when taking the total amount of the self-emulsifying composition as 100 mass %, 70 to 90 mass % of at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids, pharmaceutically acceptable salts thereof, and esters of the same, 0.5 to 6 mass % of water and 1 to 29 mass % of an emulsifying agent that comprises a polyoxyethylene sorbitan fatty acid ester (and that further contains a polyoxyl castor oil optionally, with the proviso that the emulsifying agent does not include lecithin) and which contains 3 to 40 parts by mass of lecithin relative to 100 parts by weight of the ω3 polyunsaturated fatty acid or the like. This self-emulsifying composition exhibits excellent self-emulsifying properties, composition dispersibility, emulsion stability and absorbability, and does not contain ethanol or a polyhydric alcohol or contains the same only in a low concentration. The self-emulsifying composition is useful for food and medicine. | 06-09-2016 |
| 20160158272 | OPHTHALMIC COMPOSITIONS COMPRISING POLYETHER SUBSTITUTED POLYMERS - The present invention relates to ophthalmic solutions and devices comprising at least one water soluble polymer having a molecular weight of at least about 500,000 Daltons and comprising linear or branched polyether pendant groups having a molecular weight of at least about 300. | 06-09-2016 |
| 20160177220 | LIPID COMPOSITIONS COMPRISING TRIACYLGLYCEROL WITH LONG-CHAIN POLYUNSATURATED FATTY ACIDS AT THE SN-2 POSITION | 06-23-2016 |
| 20160184252 | COMPOSITIONS COMPRISING 15-HEPE AND METHODS OF TREATING OR PREVENTING FIBROSIS USING SAME - The present disclosure provides compositions comprising 15-HEPE and methods of using same for treating and/or preventing fibrosis in a subject in need thereof. | 06-30-2016 |
| 20160374977 | Composition for Treatment of Mold - A composition and method of treating patients diagnosed with NAFLD is disclosed. The composition contains n-3 polyunsaturated fatty acids (PUFAs) for treatment of NAFLD patients, wherein the amount of PCB 153 in the composition has been minimized. The composition is administered to a patient in a sufficient amount and for a sufficient time to increase the level of n-3 PUFAs or to correct a deficiency of n-3 PUFAs in the patient's blood. The method increases the level of n-3 PUFAs without contributing to the body burden of PCB 153. | 12-29-2016 |
